Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 16/20 | 0.38 |
| ▸ | MTOR | P42345 | 3/20 | 0.34 |
| ▸ | RICTOR | Q6R327 | 2/20 | 0.34 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.34 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 0.34 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2894354 | 0.92 | GCK (0.41) | GCKMTORRICTORRPTORMAPKAP1 | |
| SCHEMBL2896807 | 0.90 | GCK (0.40) | GCK | |
| SCHEMBL2896897 | 0.86 | GCK (0.42) | GCK | |
| SCHEMBL2896829 | 0.86 | MTOR (0.30) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL2899334 | 0.84 | GCK (0.36) | GCK | |
| SCHEMBL2899366 | 0.84 | GCK (0.48) | GCKP2RX7 | |
| SCHEMBL2902502 | 0.83 | GCK (0.38) | GCKP2RX7 | |
| SCHEMBL2897151 | 0.82 | GCK (0.39) | GCK | |
| SCHEMBL13477854 | 0.81 | GCK (0.38) | GCK | |
| SCHEMBL2901604 | 0.81 | KCNH2 (0.38) | GCKP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318746-B2 | Nitrogen-containing five-membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318746-B2 | Nitrogen-containing five-membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318746-B2 | Nitrogen-containing five-membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20100130446-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAS COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130446-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAS COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130446-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAS COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2149550-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130446-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND | GCKR, GCK, SLC5A1 | GCK 2/4885MTOR 164/4885RICTOR 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.